Top Story Today
Novartis Paid $12 Billion for Avidity. Then the Roof Started Leaking.
Novartis shelled out $12 billion (a 46% premium) to acquire Avidity Biosciences and its muscle-targeting RNA platform, only to watch the HARBOR Phase 3 trial in myotonic dystrophy fail its primary endpoint weeks later. The drug didn't improve hand-opening function versus placebo. The silver lining: Avidity's lead DMD asset, del-zota, still has genuinely strong data, with dystrophin levels hitting about 25% of normal in early trials. But investors aren't buying the nuance. Guggenheim had flagged the failed drug as "crucial" for validating the entire deal, and one major shareholder publicly called for management accountability.
Why it matters: At $12 billion, every future readout from Avidity's antibody-oligonucleotide conjugate platform will be judged not just as science, but as a verdict on Novartis's capital allocation strategy. One more stumble could turn investor skepticism into a full credibility crisis.
Read more →Deals and Dealmaking
AstraZeneca Drops $2 Billion Just to Date Summit's Cancer Drug
AstraZeneca bought a 12% stake in Summit Therapeutics for roughly $2 billion, gaining the right to co-fund trials combining Summit's ivonescimab with AstraZeneca's ADC portfolio. Ivonescimab beat Keytruda in lung cancer, extending median survival by eight months. No licensing rights yet; this is a very expensive first date with a potential $15 billion deal still looming.
Read more →Merck Pays $400M for a Cancer Drug That Hasn't Touched a Human
Merck licensed a preclinical KRAS G12D inhibitor from China's SciBrunch for $400 million upfront ($2.1 billion total), betting on a "molecular glue" mechanism that pins down a protein scientists called undruggable for 40 years. Competitors like Astellas and Revolution Medicines already have candidates in Phase 3. Merck is late but banking on differentiation.
Read more →Novo Bets $2.6 Billion on a Pill Nobody's Tested in Humans
Novo Nordisk licensed HRS-1596, a once-weekly oral GLP-1/GIP agonist, from China's Hengrui for up to $2.6 billion. The drug hasn't entered clinical trials outside China. It's a defensive play: Lilly's tirzepatide is pressuring Wegovy, and Novo needs more shots on goal. The $300 million upfront is a rounding error on Novo's balance sheet.
Read more →Telix Buys the Radioactive Cheese Factory for $2.35 Billion
Australian radiopharmaceutical company Telix is acquiring ITM Isotope Technologies Munich, the world's largest producer of lutetium-177, for up to $2.35 billion. In a sector where the raw ingredients are scarcer than the drugs, owning isotope supply could be the ultimate competitive moat. Telix shares dipped on dilution concerns.
Read more →Clinical Trials and Pipeline
The Eye Drug That Rose From Repeated Failure
Kodiak Sciences matched Eylea's efficacy in wet AMD while 54% of patients went six full months between injections. The stock surged roughly 166%. This is the same company that suffered major Phase 3 setbacks in 2022 and 2023 and was left for dead. Same molecule, smarter trial design, completely different outcome.
Read more →Novartis's MS Drug Calms Immune Cells Instead of Killing Them
Remibrutinib beat teriflunomide on relapse rates in two Phase 3 MS trials with roughly 2,000 patients, and showed no liver toxicity signal. That safety detail matters: competitor Sanofi's BTK inhibitor hit liver trouble, and Merck's failed outright. Analysts see $3 billion in peak sales potential for a drug that quiets immune cells rather than destroying them.
Read more →Genetics Promised These Heart Drugs Would Work. Patients Disagreed.
Novartis's pelacarsen and Novo's ziltivekimab both nailed their biomarker targets in massive cardiovascular trials, yet neither reduced heart attacks, strokes, or death. Both programs had among the strongest genetic validation in medicine. The lesson: genetic evidence roughly doubles your odds of success, but doubling a low number still gives you a low number.
Read more →Roche Kills Its Muscle-Preserving Obesity Antibody
Roche pulled the plug on emugrobart, an anti-myostatin antibody designed to prevent muscle loss during GLP-1-driven weight loss, after a Phase 2 interim analysis showed it wouldn't hit efficacy goals. Another non-incretin obesity approach bites the dust. Roche's broader obesity portfolio (led by enicepatide) remains intact, but the flanking strategy just lost its most interesting card.
Read more →Big Picture
The Antibiotic Hospitals Need Just Lost Its Maker
Merck stopped supplying Recarbrio, a last-resort antibiotic for ventilator-acquired pneumonia and resistant infections, from the U.S. market. Drug-resistant infections hit 2.8 million Americans per year and kill over 35,000. The PASTEUR Act, which would pay companies a subscription fee for critical antibiotics, has been floating in Congress since 2020 and has never received a floor vote.
Read more →AI-Designed Packaging Keeps mRNA Vaccines Stable Without a Freezer
MIT researchers used a Bayesian optimization system called AGENT to design lipid nanoparticles that kept mRNA vaccines stable at room temperature for a year and at body temperature for two months. Mice vaccinated with the reformulated doses mounted immune responses matching freshly prepared vaccines. Still preclinical, but a credible path toward eliminating cold-chain barriers for billions of people.
Read more →